Literature DB >> 28776361

First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome.

B Palterer1, G Vitiello, D Cammelli.   

Abstract

Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28776361     DOI: 10.4081/reumatismo.2017.923

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  4 in total

1.  Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment.

Authors:  Irina Lerman; Christopher T Richardson
Journal:  Cureus       Date:  2019-09-26

Review 2.  Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature.

Authors:  Bruno Corrado; Gianluca Ciardi; Laura Lucignano
Journal:  Neurol Int       Date:  2020-11-24

Review 3.  Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.

Authors:  Ryohei Ono; Tomohiro Kumagae; Mari Igasaki; Takaaki Murata; Masaki Yoshizawa; Izumi Kitagawa
Journal:  J Med Case Rep       Date:  2021-03-22

Review 4.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.